Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system

Trends in Immunology

Volumn 33, Issue 7, 2012, Pages 357-363

  Moran Crusio, Kelly ^a   Reavie, Linsey B ^a   Aifantis, Iannis ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYSTEINE PROTEINASE; PROTEASOME; RING FINGER PROTEIN; UBIQUITIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; B CELL LYMPHOMA; CANCER THERAPY; CELL FATE; DRUG MECHANISM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LEUKEMOGENESIS; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTO ONCOGENE; REVIEW;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINEAGE; HEMATOPOIETIC STEM CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84862677023     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.01.009     Document Type: Review

References (83)

1. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132:631-644.
2. Mikkola H.K., Orkin S.H. The journey of developing hematopoietic stem cells. Development 2006, 133:3733-3744.
3. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068-1074.
4. Wilson A., Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 2006, 6:93-106.
5. Jude C.D., et al. Leukemia and hematopoietic stem cells: balancing proliferation and quiescence. Cell Cycle 2008, 7:586-591.
6. Warr M.R., et al. Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011, 3:681-701.
7. Calvi L.M., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
8. Kiel M.J., Morrison S.J. Maintaining hematopoietic stem cells in the vascular niche. Immunity 2006, 25:862-864.
9. Zhang J., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
10. Parmar K., et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5431-5436.
11. Trumpp A., et al. Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 2010, 10:201-209.
12. Lacombe J., et al. Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood 2010, 115:792-803.
13. Laurenti E., et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008, 3:611-624.
14. Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
15. North T., et al. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 1999, 126:2563-2575.
16. Park I.K., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
17. Reavie L., et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat. Immunol. 2010, 11:207-215.
18. Wang Q., et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3444-3449.
19. Wilson A., et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004, 18:2747-2763.
20. Matsuoka S., et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008, 22:986-991.
21. Thompson B.J., et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 2008, 205:1395-1408.
22. Li Z., et al. Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J. Biol. Chem. 2006, 281:20643-20649.
23. Bhat K.P., Greer S.F. Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation. Biochim. Biophys. Acta 2011, 1809:150-155.
24. Tuoc T.C., Stoykova A. Roles of the ubiquitin-proteosome system in neurogenesis. Cell Cycle 2010, 9:3174-3180.
25. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
26. Hoeller D., et al. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev. Cancer 2006, 6:776-788.
27. Pickart C.M., Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 2004, 1695:55-72.
28. Mukhopadhyay D., Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007, 315:201-205.
29. Song L., Rape M. Reverse the curse--the role of deubiquitination in cell cycle control. Curr. Opin. Cell Biol. 2008, 20:156-163.
30. Bernassola F., et al. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008, 14:10-21.
31. Nakayama K.I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006, 6:369-381.
32. Kane R.C., et al. Velcade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8:508-513.
33. Kane R.C., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 2007, 13(18 Pt 1):5291-5294.
34. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
35. Petroski M.D. The ubiquitin system, disease, and drug discovery. BMC Biochem. 2008, 9(Suppl. 1):pS7.
36. Aghajan M., et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 2010, 28:738-742.
37. Orlicky S., et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol. 2010, 28:733-737.
38. Love K.R., et al. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat. Chem. Biol. 2007, 3:697-705.
39. Schwickart M., et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-107.
40. Langdon W.Y., et al. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:1168-1172.
41. Schmidt M.H., Dikic I. The Cbl interactome and its functions. Nat. Rev. Mol. Cell Biol. 2005, 6:907-918.
42. Goh E.L., et al. c-Cbl is a negative regulator of GH-stimulated STAT5-mediated transcription. Endocrinology 2002, 143:3590-3603.
43. Jehn B.M., et al. c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1. J. Biol. Chem. 2002, 277:8033-8040.
44. Zeng S., et al. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 2005, 105:226-232.
45. Rathinam C., et al. The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells. Genes Dev. 2008, 22:992-997.
46. Wang Z., et al. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 2009, 113:4856-4865.
47. Rathinam C., et al. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010, 18:341-352.
48. Bacher U., et al. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann. Hematol. 2010, 89:643-652.
49. Barresi V., et al. Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. Leuk. Res. 2010, 34:1539-1542.
50. Fernandes M.S., et al. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J. Biol. Chem. 2010, 285:32596-32605.
51. Rocquain J., et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010, 10:401.
52. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
53. Rathinam C., et al. The E3 ligase Itch is a negative regulator of the homeostasis and function of hematopoietic stem cells. Nat. Immunol. 2011, 12:399-407.
54. Tetzlaff M.T., et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3338-3345.
55. Tsunematsu R., et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J. Biol. Chem. 2004, 279:9417-9423.
56. Onoyama I., et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 2007, 204:2875-2888.
57. Kaelin W.G. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 2008, 8:865-873.
58. Simon M.C., Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 2008, 9:285-296.
59. Takubo K., et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010, 7:391-402.
60. Nijman S.M., et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 2005, 17:331-339.
61. D'Andrea A.D., Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 2003, 3:23-34.
62. Joenje H., Patel K.J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2001, 2:446-457.
63. Kim J.M., et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell 2009, 16:314-320.
64. Parmar K., et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 2010, 28:1186-1195.
65. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996, 10:1054-1072.
66. Vazquez A., et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7:979-987.
67. Honda R., et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420:25-27.
68. Jones S.N., et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
69. Montes de Oca Luna R., et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
70. Marine J.C., et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006, 13:927-934.
71. Lee J.T., Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17:86-92.
72. Weissman A.M., et al. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat. Rev. Mol. Cell Biol. 2011, 12:605-620.
73. Ludwig R.L., et al. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 1996, 16:4952-4960.
74. Rowan S., et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 1996, 15:827-838.
75. Abbas H.A., et al. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 2010, 7:606-617.
76. Spangrude G.J., et al. Purification and characterization of mouse hematopoietic stem cells. Science 1988, 241:58-62.
77. Osawa M., et al. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996, 273:242-245.
78. Kiel M.J., et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005, 121:1109-1121.
79. Wilson A., et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008, 135:1118-1129.
80. Schwartz A.L., Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 2009, 49:73-96.
81. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2001, 2:169-178.
82. Rotin D., Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2009, 10:398-409.
83. Lipkowitz S., Weissman A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 2011, 11:629-643.